Show results for
Refine by
Therapeutic Antibody Development Suppliers Serving Armenia
49 companies found
based inMilpitas, CALIFORNIA (USA)
ASC Therapeutics is a fully incorporated biopharmaceutical company focusing on the development of curative therapeutic products that are enabled by our proprietary gene editing platform, TARGATT and other gene editing technologies developed after 12 ...
Genome editing technologies enables permanent modifications to the genome by harnessing the activities of certain enzymes (e.g. nucleases and integrase) and invoking DNA repair mechanisms at specific locations in the genome. As a therapeutic ...
based in
Tectonic Therapeutic, Inc., a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs, announced merger with AVROBIO, Inc. The combined company will ...
based inAustin, TEXAS (USA)
Direct Biologics is a leader in regenerative medicine, focusing on the development of next-generation bioactive products derived from stem cells. Their innovative technology centers on Extracellular Vesicle (EV) products, which are formulated from ...
based inKleinostheim, GERMANY
SCHWIND eye-tech-solutions is one of the technology leaders for eye lasers for refractive and therapeutic corneal surgery. We develop, produce and market a comprehensive product portfolio for the treatment of vision defects and corneal diseases. ...
based inSeongnam-si, SOUTH KOREA
LISCure Biosciences Provides Novel Therapeutics to Patients with Refractory Diseases Using the LMT Platform. LISCure is developing the world’s first injectable immuno-oncology program using non-pathogenic microorganisms. We focus on the development ...
The LMT (LISCure Microbiology-based Technology) platform is an innovative tool to keep discovering and analyzing microbial and genome-based drug candidates. LMT (LISCure Microbiology-based Technology) Platform Consists of the Therapeutic Screening ...
based inVictoria, BRITISH COLUMBIA (CANADA)
IPA (ImmunoPrecise Antibodies NASDAQ: IPA ) is a biotherapeutic research company that brings industry leading antibody discovery services and complex artificial intelligence technologies together - to lead its pharmaceutical partners into the era of ...
based inCarlsbad, CALIFORNIA (USA)
ScienCell Research Laboratories is an expanding biotechnology company established in 1999. Our mission is to research and develop cell products for experimental use. ScienCell provides a variety of high quality normal human and animal cells, cell ...
based inGangnam-gu, SOUTH KOREA
MitoImmune Therapeutics Inc. is a drug discovery and development biotech company that harnesses the power of mitochondria and its proprietary technology targeting mitochondria as the source for developing new potential breakthrough therapeutics. Our ...
based inEmeryville, CALIFORNIA (USA)
Metagenomi is a biotechnology company at the forefront of genetic engineering, striving to leverage microbial evolution to develop groundbreaking therapies for diseases. The company employs metagenomics, the study of genetic material recovered ...
based inBeloit, WISCONSIN (USA)
We are innovators who revolutionized the reliable production of Mo-99. We are dedicated to preserving the environment using non-uranium production methods. We are pioneers working with industry leaders to develop and commercialize new diagnostics ...
based inEmeryville, CALIFORNIA (USA)
Nutcracker Therapeutics is an early-stage company that is pioneering a revolutionary therapeutic development and manufacturing platform designed to enable the advancement of RNA-based treatments for as many diseases as possible, as fast as possible. ...
based inNewark, CALIFORNIA (USA)
ACD - a Bio-Techne brand, shortens the path to personalized medicine and enables research, drug development and clinical applications by unlocking the power of RNA. ACD is a leader in the emerging field of molecular pathology, developing cell- and ...
based inWaltham, MASSACHUSETTS (USA)
Third Pole Therapeutics develops and delivers critical life-sustaining cardio-pulmonary therapies. Warren Zapol, M.D., Third Pole’s founder, invented the first use for inhaled nitric oxide (iNO) for the treatment of hypoxic respiratory failure in ...
based inNew Hope, PENNSYLVANIA (USA)
We are a biomedical innovation company focused on developing transformative therapeutic products for large unmet clinical needs in procedure-based medicine. Our partnership-enabled business model focuses on forging strategic collaborations with ...
based inParis Cedex 06, FRANCE
We develop and commercialize patented, disruptive liquid biopsy tests – innovative blood tests in oncology – based on a unique cell isolation technology called ISET (Isolation by SizE of Tumor cells) and cyto-molecular profiling of Circulating Tumor ...
based inMorgan Hill, CALIFORNIA (USA)
Anaerobe Systems produces the world’s only true pre-reduced anaerobically sterilized (PRAS) culture media: poured and packaged under anaerobic conditions. Founded over 40 years ago, for scientists by scientists, Anaerobe Systems has discovered ...
based inVancouver, BRITISH COLUMBIA (CANADA)
InMed Pharmaceuticals is a global leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, including clinical and preclinical programs targeting the treatment of diseases with high unmet ...
based inPozuelo de Alarcón, SPAIN
We are a specialized pharmaceutical company engaged in the research, development, manufacture and marketing of pharmaceutical products. Our operations encompass the marketing of both our own and licensed products and the provision of services, such ...
based inFlagstaff, ARIZONA (USA)
Symple Surgical is an exciting start-up Medical Device company focused on developing novel therapeutic technologies through controlled Microwave Ablation. Our technologies are thoughtfully designed to be familiar and easy to use by the operator ...
based inRockville, MARYLAND (USA)
Since the treatment of our first oncology patient in 2015, AbelZeta has been able to build best-in-class and best-in-disease potential pipeline, leading to the licensing of two CD20-directed autologous CAR-Ts to Janssen Biotech in 2023. Our goal is ...
